FierceBiotech1h
Sanofi-backed Abcuro raises $200M series C to fund pivotal trial of KLRG1 antibody
Sanofi-backed Abcuro has secured $200 million in series C funds to power its anti-KLRG1 antibody through a phase 2/3 muscle ...
FierceBiotech1h
Biogen enlists Royalty for pursuit of lupus crown, securing $250M to fund phase 3 program
Biogen has bagged $250 million to advance a key pipeline prospect. | Biogen has bagged $250 million to advance a key pipeline ...
FierceBiotech20h
GSK plans to move vaccine R&D center from Rockville, Maryland, to the Boston area
After calling Rockville, Maryland, home for more than eight years, Big Pharma GSK is planning to move its vaccine and ...
FierceBiotech20h
Pfizer's investigational candidate combo cuts prostate cancer progression by 49% in phase 1
After an apparent accidental early release, Pfizer has revealed phase 1 data showing its investigational candidate, alongside ...
FierceBiotech19h
Inspire Medical discloses DOJ civil false claims investigation
During its fourth-quarter earnings call this week, Inspire Medical disclosed that it has become the subject of a civil probe ...
FierceBiotech23h
Journey of Voyager’s ALS gene therapy to clinic hindered by need to find alternative payload
The candidate in question is VY9323, an AAV gene therapy combining a highly potent pri-miRNA against superoxide dismutase 1 ...